All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
In the past decade, tremendous progress has been made in the field of immunotherapy, especially in the field of T cell therapy. This method uses engineered T cells with artificial chimeric antigen receptors (CAR) as an example, which can recognize specific proteins expressed on the surface of tumor cells, resulting in rapid activation and killing of tumor cells. Although clinical success has been achieved in a few tumor types, the types of surface proteins that can be targeted by this technology are limited, which severely limits the development of CAR-T cells for multiple tumor types. Besides, the targeted surface proteins so far are also expressed on normal cells, leading to CAR-T-mediated killing of non-cancer cells and potentially life-threatening side effects related to the intensity of the subsequent immune response.
To solve the problem of the scope and selectivity of CAR-T, researchers are turning to a method of engineering T cells based on T cell receptors (TCR-T). The ability of TCR to selectively recognize target cells comes from its unique ability to recognize cell surface "antigens". These antigens can be used as selective identifiers for malignant cells, and more and more tumor-related antigens are being identified, enabling the engineering of a potent and selective TCR-T directed against cancer.
As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs masters the most advanced CAR/TCR technology. With state-of-art TCR development platforms and advanced technologies, Creative Biolabs is capable of offering a broad range of TCR-T early development services, including TCR engineered T cell biomarker identification and selection, design, construction, and analysis. Moreover, our one-stop TCR development services also provide you the preclinical test.
Our one-stop TCR-T therapy development services include but not limited to:
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION